Fish oil (medical use)

Fish oil, sold under the brand name Omegaven, is a fatty acid emulsion.[2] It is used for total parenteral nutrition (feeding directly into a venous catheter), e.g. in short bowel syndrome.[2] It is rich in omega-3 fatty acids.[2]

Fish oil
Clinical data
Trade namesOmegaven
AHFS/Drugs.comProfessional Drug Facts
License data
Pregnancy
category
    Dependence
    liability    		Intravenous
    Drug classIntravenous nutritional products
    ATC code
    • none
    Legal status
    Legal status

    It has gained popularity in children in preference to the more commonly used Intralipid after case reports that it reduced the risk of liver damage.[3]

    A recent study indicated that the use of Omegaven may be an appropriate intervention strategy for newborns with a very low birth weight, gastrochisis, and jejunal atresia.[4]

    It is currently undergoing a clinical trial at National Taiwan University Hospital.[5]

    Although the use of Omegaven in children in the United States is experimental, the use of it in adults in Europe is less controversial.[6] In European studies, Omegaven has been associated with a reduction in psoriasis, when contrasted to administration of omega-6 fatty acid Lipoven.[7] Omegaven has also been associated with reduced mortality and antibiotic use during hospital stays.[8]

    Omegaven was approved for use in the United States on July 27, 2018,[9] and is available to patients on the US market by prescription effective November 15, 2018.[10]

    References
    1. "Fat emulsion Use During Pregnancy". Drugs.com. 4 May 2020. Retrieved 12 May 2020.
    2. "Omegaven- fish oil injection, emulsion". DailyMed. 6 August 2018. Retrieved 13 May 2020.
    3. Gura KM, Duggan CP, Collier SB, et al. (2006). "Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management". Pediatrics. 118 (1): e197–201. doi:10.1542/peds.2005-2662. PMID 16818533.
    4. Christensen RD, Henry E, Wiedmeier SE, Burnett J, Lambert DK (2007). "Identifying patients, on the first day of life, at high-risk of developing parenteral nutrition-associated liver disease". Journal of Perinatology. 27 (5): 284–90. doi:10.1038/sj.jp.7211686. PMID 17344923.
    5. Clinical trial number NCT00172198 for "Omegaven (w-3 Fish Oil) Supplemented Parenteral Nutrition in Subjects of SICU." at ClinicalTrials.gov
    6. A Doctor's Push For Drug Pits Him Against Its Maker at The Wall Street Journal
    7. Mayser P, Grimm H, Grimminger F (2002). "n-3 fatty acids in psoriasis". Br. J. Nutr. 87. Suppl 1: S77–82. doi:10.1079/bjn2001459. PMID 11895157.
    8. Heller AR, Rössler S, Litz RJ, et al. (2006). "Omega-3 fatty acids improve the diagnosis-related clinical outcome". Crit. Care Med. 34 (4): 972–9. doi:10.1097/01.CCM.0000206309.83570.45. PMID 16484909.
    9. "Drug Approval Package: Omegaven (fish oil triglycerides)". U.S. Food and Drug Administration (FDA). 24 August 2018. Retrieved 12 May 2020.
    10. Research, Center for Drug Evaluation and. "Investigational New Drug (IND) Application - How to request Omegaven for Expanded Access Use". www.fda.gov. Retrieved 2019-02-15.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.